Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Tursi

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Nature|December 13, 2023
Modified messenger-RNA components alter the encoded proteinNicholas J Tursi, David B Weiner
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|February 22, 2023
Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunityNicholas J Tursi, Ziyang Xu, Daniel W Kulp, et al.
Frontiers in Immunology|October 15, 2025
Advances in molecular adjuvants for nucleic acid vaccinesCasey E Hojecki, Nicholas J Tursi, Cory Livingston, et al.
Frontiers in Immunology|March 8, 2021
Uropathogenic <i>Escherichia coli</i> Infection Compromises the Blood-Testis Barrier by Disturbing mTORC1-mTORC2 BalanceYongning Lu, Miao Liu, Nicholas J Tursi, et al.
Frontiers in Medical Technology|January 20, 2022
Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious DiseasesZiyang Xu, Ami Patel, Nicholas J Tursi, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Notch2 signaling instructs viral and bacterial TLR responsiveness in B cellsJennifer Londregan, Isaiah Rozich, Brian T Gaudette, et al.
Journal for Immunotherapy of Cancer|December 2, 2024
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cellsDaniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, et al.
Molecular Therapy Oncolytics|September 12, 2022
<i>In vivo</i> DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformePratik S Bhojnagarwala, Ryan P O'Connell, Daniel Park, et al.
NPJ Vaccines|December 13, 2025
Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccineJames Fuller, Erik Kvam, Sandrine Creton, et al.
NPJ Vaccines|November 22, 2025
Electroporation and LNP-mediated delivery of plasmid DNA-encoded H5N1 influenza virus hemagglutinin support protection against highly pathogenic avian influenzaEbony N Gary, Nicholas J Tursi, Casey E Hojecki, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Nature|December 13, 2023
Modified messenger-RNA components alter the encoded proteinNicholas J Tursi, David B Weiner
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|February 22, 2023
Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunityNicholas J Tursi, Ziyang Xu, Daniel W Kulp, et al.
Frontiers in Immunology|October 15, 2025
Advances in molecular adjuvants for nucleic acid vaccinesCasey E Hojecki, Nicholas J Tursi, Cory Livingston, et al.
Frontiers in Immunology|March 8, 2021
Uropathogenic <i>Escherichia coli</i> Infection Compromises the Blood-Testis Barrier by Disturbing mTORC1-mTORC2 BalanceYongning Lu, Miao Liu, Nicholas J Tursi, et al.
Frontiers in Medical Technology|January 20, 2022
Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious DiseasesZiyang Xu, Ami Patel, Nicholas J Tursi, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Notch2 signaling instructs viral and bacterial TLR responsiveness in B cellsJennifer Londregan, Isaiah Rozich, Brian T Gaudette, et al.
Journal for Immunotherapy of Cancer|December 2, 2024
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cellsDaniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, et al.
Molecular Therapy Oncolytics|September 12, 2022
<i>In vivo</i> DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformePratik S Bhojnagarwala, Ryan P O'Connell, Daniel Park, et al.
NPJ Vaccines|December 13, 2025
Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccineJames Fuller, Erik Kvam, Sandrine Creton, et al.
NPJ Vaccines|November 22, 2025
Electroporation and LNP-mediated delivery of plasmid DNA-encoded H5N1 influenza virus hemagglutinin support protection against highly pathogenic avian influenzaEbony N Gary, Nicholas J Tursi, Casey E Hojecki, et al.
Pageof 4